Pharmacist involvement in primary care improves hypertensive patient clinical outcomes

被引:81
作者
Sookaneknun, P [1 ]
Richards, RM
Sanguansermsri, J
Teerasut, C
机构
[1] Mahasarakham Univ, Fac Pharmaceut & Hlth Sci, Maha Sarakham 44150, Thailand
[2] Chiang Mai Univ, Fac Pharm, Chiang Mai, Thailand
[3] Mahasarakham Hosp, Maha Sarakham, Thailand
关键词
blood pressure; hypertension; pharmaceutical care;
D O I
10.1345/aph.1D605
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The practice of pharmaceutical care in primary care settings in Thailand is currently not generally accepted. Objective: To evaluate the effect of pharmacist involvement in treatment with hypertensive patients in primary care settings. Methods: The treatment objective was to stabilize the blood pressure (BP) of hypertensive patients in accordance with the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure guidelines. Patients were randomly assigned to a pharmacist-involved group (treatment) or a group with no pharmacist involvement (control). Pre- and post-test BPs, tablet counts, lifestyle modifications, and pharmacists' recommendations were recorded. The 6-month study was carried out in Mahasarakham University pharmacy and 2 primary care units. Patients were monitored monthly by reviewing their medications and supported by providing pharmaceutical care and counseling. Results: From a total of 235 patients, the treatment group (n=118) had a significant reduction in both systolic (S) and diastolic (D) BP compared with the 117 patients of the control group (p=0.037, 0.027, respectively). The 158 patients (76 treatment, 82 control) with BPs greater than or equal to140/90 mm Hg at the beginning of the study showed significant BP reductions (p=0.002 SBP, 0.008 DBP). The proportion of 158 patients whose BP became stabilized was higher in the treatment group (p=0.017). The treatment group showed significantly better adherence (p=0.014) and exercise control (p=0.012) at the end of the study. Physicians accepted 42.72% of medication modifications and 5.34% of the suggestions for additional investigations. Conclusions: Hypertensive patients who received pharmacist input achieved a significantly greater benefit in BP reduction, BP control, and improvement in adherence rate and lifestyle modification.
引用
收藏
页码:2023 / 2028
页数:6
相关论文
共 18 条
[1]   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[2]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[3]   Physician-pharmacist comanagement of hypertension: A randomized, comparative trial [J].
Borenstein, JE ;
Graber, G ;
Saltiel, E ;
Wallace, J ;
Ryu, S ;
Jackson, A ;
Deutsch, S ;
Weingarten, SR .
PHARMACOTHERAPY, 2003, 23 (02) :209-216
[4]  
Garcao Jove A, 2002, J Am Pharm Assoc (Wash), V42, P858, DOI 10.1331/108658002762063691
[5]   OPPORTUNITIES AND RESPONSIBILITIES IN PHARMACEUTICAL CARE [J].
HEPLER, CD ;
STRAND, LM .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1990, 47 (03) :533-543
[6]   Elevated systolic blood pressure as a cardiovascular risk factor [J].
Kannel, WB .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (02) :251-255
[7]   Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients [J].
Klungel, OH ;
Kaplan, RC ;
Heckbert, SR ;
Smith, NL ;
Lemaitre, RN ;
Longstreth, WT ;
Leufkens, HGM ;
de Boer, A ;
Psaty, BM .
STROKE, 2000, 31 (02) :420-424
[8]   Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension [J].
Mehos, BM ;
Saseen, JJ ;
MacLaughlin, EJ .
PHARMACOTHERAPY, 2000, 20 (11) :1384-1389
[9]   Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke - The Systolic Hypertension in the Elderly Program (SHEP) [J].
Perry, HM ;
Davis, BR ;
Price, TR ;
Applegate, WB ;
Fields, WS ;
Guralnik, JM ;
Kuller, L ;
Pressel, S ;
Stamler, J ;
Probstfield, JL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (04) :465-471
[10]  
ROSENTHAL WM, 2001, HDB NONPRESCRIPTION, P917